ProQR Therapeutics N.V. (PRQR)

Market Cap	158.04M +1.4%
Revenue (ttm)	19.19M -16.4%
Net Income	-49.53M
EPS	-0.47
Shares Out	105.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	160
Open	n/a
Previous Close	1.500
Day's Range	n/a
52-Week Range	1.070 - 3.100
Beta	0.09
Analysts	Strong Buy
Price Target	7.67 (+411.33%)
Earnings Date	Mar 12, 2026

About PRQR

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metab...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 18, 2014
• Employees: 187
• Stock Exchange: NASDAQ
• Ticker Symbol: PRQR
• Website: https://www.proqr.com

Financial Performance

In 2025, ProQR Therapeutics's revenue was 16.35 million, a decrease of -16.36% compared to the previous year's 19.55 million. Losses were -42.18 million, 51.9% more than in 2024.

Financial numbers in EUR

Analyst Summary

According to 6 analysts, the average rating for PRQR stock is "Strong Buy." The 12-month stock price target is $7.67, which is an increase of 411.33% from the latest price.

Price Target

$7.67

(411.33% upside)

Analyst Consensus: Strong Buy